We continue to focus our efforts in the therapeutic areas of oncology and immunology, and have succeeded in rapidly advancing our two lead clinical programs - BL-8040 for the treatment of acute myeloid leukemia , stem cell mobilization and other hematological indications; and BL-7010 for the treatment of celiac disease.
http://ift.tt/1lJMd9R
http://ift.tt/1lJMd9R
No comments:
Post a Comment